Skip to content

Primary pOsterioR TRacheopexy prevents collapse of the trachea in newborns with esophageal AtresIa and Tracheomalacia

Primary pOsterioR TRacheopexy prevents collapse of the trachea in newborns with esophageal AtresIa and Tracheomalacia - Primary Posterior Tracheopexy prevents tracheal collapse

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56519
Enrollment
45
Registered
2024-01-31
Start date
2025-05-09
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

collapse of the windpipe Tracheomalacia

Interventions

randomization between performing a PPT or no-PPT

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: Patients with esophageal atresia type with a distal tracheoesophageal fistula (TEF), with tracheomalacia, written informed consent by both parent(s) or legal representative(s).

Exclusion criteria

Exclusion criteria: Patients with esophageal atresia without a distal TEF, premature neonates

Design outcomes

Primary

MeasureTime frame
Primary endpoint: The difference in the degree of tracheal collapse between the PPT and the no-PPT group measured in percentage of the tracheal diameter, during: - An intra-operative bronchoscopy after freeing the trachea and esophagus and, in case of PPT-group, the PPT, but before the surgical correction of EA, through the ventilation tube in the surgical theatre.

Secondary

MeasureTime frame
Key secondary endpoints: The difference in the degree of tracheal collapse between the PPT and the no-PPT group in percentages as measured during: - a first postoperative bronchoscopy through the ventilation tube during routine extubation in the pediatric or neonatal intensive care unit - a second postoperative bronchoscopy that is conducted under general anesthesia in the surgical theatre after approximately 2-6 months. This bronchoscopy serves as a key secondary endpoint and aims to determine whether the effect of PPT is sustained and/or if the TM deteriorates beyond the first 2 months.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)